Zantac 75 Pediatric Exclusivity Opposed In Novopharm Petition
This article was originally published in The Tan Sheet
Executive Summary
Awarding six months of pediatric exclusivity to Glaxo's Zantac 75 would be "contrary to the public interest because it would frustrate the intent of Congress," Novopharm argues in a Nov. 19 citizen petition to FDA.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning